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Abstract
Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in
the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013
on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications
represents a major advance in the management of HIV infection, and each of these three drugs can be expected to
continue to be an important component of ARV combination regimens.
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The recent approval by the Food and Drug Administra-
tion (FDA) of Elvitegravir (EVG) as an anti-HIV inte-
grase strand transfer inhibitor (INSTI) is good news for
patients who will want to take a potent once-daily single
tablet antiretroviral regimen (STR). INSTIs target the
HIV enzyme integrase through a selective effect on
strand transfer. This is a result of both the binding of
the inhibitor to the specific complex between integrase
and viral DNA, resulting in displacement of the reactive
30 end of the viral DNA and chelation of the two essen-
tial magnesium ions present in the integrase active site
[1]. In general, the INSTI class of antiretroviral drugs is
active against multiple retroviruses, including primate
and nonprimate lentiviruses, and against both HIV-1
and HIV-2 [2,3]. Furthermore, these compounds seem
to be active against all subtypes of HIV-1 since the inte-
grase enzymes of these subtypes share sequence ho-
mology and behave similarly in biochemical assays [4].
Due to the fact that EVG needs to be boosted by an add-
itional drug, termed cobicistat, with which it has been
co-formulated, the new STR will consist of four separate
ingredients that also include the two potent nucleos(t)
ide reverse transcriptase inhibitors (NRTIs) emtricita-
bine (FTC) and tenofovir (TDF). The FDA approved
EVG for treatment of drug-naïve patients based on three
large clinical trials, two in drug-naïve and one in drug-
experienced patients [5-7]. The efficacy and safety of the
four drugs in the new formulation, now termed StribildW,
was evaluated in a randomized double-blind double
dummy design against a triple drug STR termed AtriplaW
that includes both FTC and TDF as well as the non-
nucleoside reverse transcriptase inhibitor (NNRTI) efavir-
enz (EFV) in a trial of 700 drug-naïve patients [5]. In a
second trial of 700 drug-naïve patients, the same four drug
STR was evaluated against a triple combination that
includes both FTC and TDF as well as the ritonavir-
boosted protease inhibitor (PI) atazanavir (ATV/r) [6]. In
these two trials, the new EVG-containing regimen was
documented to be non-inferior to AtriplaW and to TDF/
FTC plus ATV/r in terms of the proportion of previously
drug-naïve patients demonstrating viral load suppression
to below 50 copies RNA/ml after 48 weeks of treatment.
The new regimen is considered by many to have potential
advantages compared with AtriplaW because of well-
documented EFV-related toxicities (central nervous sys-
tem (CNS) and cutaneous) and the fact that some patients
may have been infected by viruses that contained the
K103N mutation or other mutations that confer resistance
against EFV. Even though any patient possessing these
mutations on the basis of standard genotyping prior to ini-
tiation of therapy would be ineligible to receive either EFV
or AtriplaW, the fact is that some patients may possess mi-
nority variants of these mutations that can only be
detected by more sensitive techniques, not available in
routine practice, and that such individuals may be
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compromised in terms of ability to respond to an EFV-
based regimen [8].
At the same time, it must be recognized that one other
INSTI is currently available for treatment and that other
members of this family of compounds are now in late
stage clinical development and may be approved for
therapy in the near future. The drug that has already
been approved is raltegravir (RAL), and it has the advan-
tage of being extremely potent as well as safe and very
well tolerated over more than five years of clinical ex-
perience [9]. Moreover, the Startmrk trial has reported
long term efficacy data of 563 previously treatment-
naive individuals over five years of therapy, and the
results reveal that RAL is virologically superior to EFV
over this time and better tolerated when either drug is
used in combination with FTC and TDF, despite the fact
that EFV can be dosed once-daily while RAL has only
been approved for use as a twice-daily drug [10]. The
Startmrk trial was a randomized double-blind study in
which RAL was dosed twice daily while patients on the
EFV arm of the study received active EFV as part of their
night-time regimen and a placebo in the morning at the
same time that patients in the RAL arm received active
drug [10]. In view of the fact that EFV possesses a far
longer plasma half-life than RAL, it can therefore be fur-
ther argued that any degree of non-adherence in the
Startmrk trial should have favoured the EFV arm. Thus,
the demonstrated superiority of RAL over EFV is even
more impressive than the data of the intent-to-treat ana-
lysis would seem to indicate (proportion with HIV RNA
< 50 c/ml at week 240 was 71% vs. 61% for RAL and
EFV, respectively (95% CI : 1.7-17.3)) [9]. Of note there
was a low level of resistance among patients with virolo-
gic failure; after 240 weeks of follow-up, only 7 patients
in the RAL group possessed resistance mutations at time
of virologic failure. There was also a benefit of RAL over
EFV in regard to lipid profile [9].
It is worth noting that RAL was approved by regulatory
agencies as a twice daily drug on the basis of the Startmrk
clinical trial. However, attempts were made to demon-
strate that RAL might be used on a once-daily basis if
dosed at 800mg once-daily (qd) as opposed to the twice-
daily (bid) dosing schedule of 400 mg that is recom-
mended [11]. Although the results of the clinical trial on
this topic, termed Qdmrk, performed in 670 drug-naïve
individuals, showed that qd dosing with RAL in combi-
nation with TDF/FTC did not meet the 10% criterion of
non-inferiority in comparison to the bid use of RAL, the
fact is that the qd use of RAL proved to be effective at
suppression of viral load to <50 copies viral RNA/ml in
more than 83% of subjects over a period of 48 weeks [12].
Moreover, the results further indicated that qd dosing with
RAL was as effective as bid RAL in almost all patients
who initiated therapy with HIV RNA <100,000 copies/ml
at baseline, suggesting as well that RAL may be a forgiving
drug in regard to occasional non-adherence [12,13]. One
of the reasons for the superiority of RAL over EFV in the
Startmrk trial may, therefore, be that occasionally missed
doses of RAL as part of a bid regimen may not impact sig-
nificantly on treatment outcome, and, as well, that RAL is
both more potent and less toxic than EFV. Of course, the
fact that RAL does not need to be boosted by a pharmaco-
logical enhancer such as ritonavir or cobicistat is another
major advantage.
Recent clinical findings suggest that a new second gen-
eration INSTI termed dolutegravir (DTG) is also super-
ior to EFV over 48 weeks of therapy, when both drugs
are used in combination with a fixed dose of once-daily
NRTIs, abacavir/lamivudine or TDF/FTC, respectively
[14]. However, a second randomized double-blind
double dummy study showed that once daily DTG was
not superior but rather non-inferior to twice daily RAL,
despite the potential advantage of being used on a qd
basis due to a long plasma half-life and an ability to bind
to the HIV integrase enzyme for a more protracted
period than either RAL or EVG [15]. DTG also has the
advantage of not requiring boosting by a pharmaco-
logical enhancer, and it is likely that DTG will be
approved by regulatory agencies during 2013, giving rise
to a situation in which three different INSTIs will be
available for treatment of HIV disease. DTG will repre-
sent a further important addition to the antiretroviral
armamentarium of drugs and has also the advantage of
having a higher genetic barrier to resistance than the
two other INSTIs (Table 1, [3]).
Of note, comparison of the different phase 3 studies of
the three INSTIs is difficult. For example, median baseline
plasma viral load was significantly higher in the Startmrk
(5.1 log10 c/ml) than in the Stribild
W studies (4.75 and 4.88
log10 c/ml) and the DTG studies (4.52 and 4.67 log10 c/ml)
[5,6,10,14,15]. This reinforces the clinical potency and effi-
cacy of RAL in mediating virologic suppression to levels
below detectability after 48 weeks of therapy, since virolo-
gic suppression is more difficult to achieve in patients who
present with high initial plasma viral loads. One of the dif-
ferences between the three INSTIs is related to inhibition
of renal tubular secretion of creatinine by both dolutegravir
and cobicistat which leads to a rapid and sustained increase
of serum creatinine, although glomerular filtration is not
affected [5,6,14,15]. Furthermore, some cases of disconti-
nuations for renal toxicity with proximal tubulopathy oc-
curred in one of the phase 3 trials of TDF/FTC/EVG/
cobicistat (5) and StribildW is contra-indicated in patients
with estimated creatinine clearance below 70 mL per
minute.
Table 1 summarizes the main characteristics of the three
INSTIs. RAL is classified by the FDA as a category C drug
for use during pregnancy, and the STR of TDF/FTC/EVG/
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cobicistat as category B, while information on this topic is
not yet available for dolutegravir. Based on package inserts,
RAL is not recommended for use during pregnancy, and
TDF/FTC/EVG/cobicistat should be used during preg-
nancy only if the potential benefit justifies the potential risk
to the fetus. RAL has been recently approved by the FDA
for use in children and adolescents aged 2–18. Chewable
pills are available for children aged 2 to 11, while the safety
and effectiveness of TDF/FTC/EVG/cobicistat and DTG in
pediatric patients less than 18 years have not been estab-
lished. A study evaluating RAL in pregnancy is ongoing
(clinicaltrials.gov NCT01618305).
Thus, we are privileged to have multiple options in
regard to the use of various INSTIs for therapy of HIV-
infected individuals. EVG is the newest INSTI to be
approved, and the promise of DTG for the future ther-
apy of HIV disease is exciting. Resistance against both
RAL and EVG have been reported on the basis of both
clinical failures (fewer with RAL than EVG) and tissue
culture drug selection studies, and it is clear from this
work that the most frequent mutations in the HIV inte-
grase gene that confer resistance against RAL also con-
fer resistance against EVG, making it highly improbable
that these two molecules might be used to salvage one
another in the event of drug resistance [3]. Indeed,
EVG can overcome only one of the three RAL-
resistance pathways (Y143). On the other hand, DTG
has demonstrated clinical activity at double the
standard dose of 50 mg bid in patients harboring
viruses resistant to RAL and/or EVG [3]. However, an
accumulation of the major RAL- or EVG-resistance
mutations may also diminish the likelihood of long-
term clinical success with DTG. At the same time,
RAL, the first approved member of the INSTI family of
drugs, remains the only integrase inhibitor to have
proven itself over more than five years of clinical ex-
perience as a fully safe and effective compound, with-
out significant drug-drug interactions, that is superior
to EFV. Although RAL is only recommended for twice
daily dosing, an analysis of the Qdmrk study and other
recent studies in which virologically suppressed
patients were switched to other regimens suggests that
a once daily dose of 800 mg RAL could represent an
option for first-line therapy in some patients presenting
with HIV RNA < 100,000 c/ml or in virologically sup-
pressed patients who wish to change regimens from a
prior first-line boosted protease inhibitor containing
regimen. Such qd dosing of RAL should be further
evaluated in randomized settings
Conclusions
Each of RAL, EVG, and DTG will continue to be im-
portant components of combination anti-HIV therapy
over many years. Although there are more long-term ef-
ficacy and safety data now available on RAL than on the
other two drugs, the use of the other options in first-line
Table 1 Major characteristics of the 3 INSTIs
Characteristic RAL EVG/cobi DTG
Dosing 400 mg bid 150/150 mg qd 50 mg qd in INSTI-naive and 50 mg bid in
INSTI-experienced patients
STR No Yes (TDF/FTC/EVG/cobi) Together with abacavir(ABC) and 3TC
To be taken with food No Yes No
In vitro activity* 33 nM (IC95) 45 ng/mL (IC95) 0.064 μg/mL (0.15 μM) (IC90)
Protein binding 83% 98 % 99.3%
Terminal half-life 9 h 12.9 h/3.5 h 15 h
Drug-drug interactions with inducers of
UGT1A1 (rifampin)
Presence of a strong CYP3A
inhibitor such as cobicistat creates
the potentialfor an increase in systemic
exposure of CYP3A substrates
with inducers of UGT1A1 (rifampin)





E92Q T66I/A/K None (accumulation of multiple mutations






RAL = raltegravir ; EVG/cobi = elvitegravir/cobicistat ; DTG = dolutegravir ; bid = twice-daily ; qd = once-daily ; TDF/FTC = tenofovir/emtricitabine ; ABC/3TC =
abacavir/lamivudine.
* in vitro protein-adjusted inhibitory concentration.
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therapy is also compelling. Due to its more favorable re-
sistance profile, DTG will probably be the only member
of the INSTI family of drugs that will be useful in both
first-line therapy as well as in subsequent HIV INSTI-
based treatment.
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